HCA vs THC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HCA and THC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HCA and THC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

HCA Healthcare is the largest for-profit hospital system in the United States, operating a network of acute-care hospitals alongside surgery centers, urgent-care clinics, freestanding emergency rooms, and physician clinics. Its strategy centers on building dense local networks in growing Sun Belt and suburban markets, where controlling a large share of care lets it negotiate better rates with commercial insurers, recruit physicians, and spread fixed costs. In the first quarter of 2026 HCA reported revenue of about $19.1 billion, up roughly 4% year over year, with net income near $1.6 billion and diluted EPS of about $7.15. Equivalent admissions rose modestly and revenue per admission grew faster, and the company reaffirmed full-year 2026 guidance of roughly $76.5 billion to $80.0 billion in revenue and $15.55 billion to $16.45 billion in adjusted EBITDA.

Full HCA guide

Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. Hospital Operations runs acute care and specialty hospitals plus affiliated outpatient facilities, imaging centers, and physician practices. United Surgical Partners International (USPI) is the ambulatory segment and operates or holds interests in hundreds of ambulatory surgery centers and surgical hospitals across dozens of states, making it the largest ASC platform in the country. Conifer Health Solutions provides revenue cycle management and value-based care services to hospitals and health systems.

Full THC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• HCA drivers: Scale and local-market density; Outpatient and ambulatory expansion.
• THC drivers: USPI ambulatory surgery leadership; Business mix shift toward higher-margin services.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is reimbursement and health-care policy. For THC, hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HCA if you believe its drivers more; THC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HCA and THC guides.

HCA. Figures are approximate and tied to the asOf date; verify live numbers before acting. HCA is generally valued as a steady, cash-generative operator rather than a high-growth stock, so its multiple reflects reimbursement stability and buyback-driven per-share growth more than rapid revenue expansion. The biggest variable is policy: the 2026 guidance already bakes in an ACA-subsidy and Medicaid hit that management is partly offsetting, so how those headwinds actually land matters more to the earnings picture than the headline multiple.

THC. Tenet trades at a modest earnings multiple typical of hospital operators, reflecting reimbursement and leverage risk, but the multiple has expanded from prior years as USPI mix shift, margin gains, and deleveraging improved earnings quality. The 2026 outlook calls for net operating revenue of roughly $21.5 to $22.3 billion. Figures are approximate and drawn from reported results and company guidance as of mid 2026.

Headline figures (approximate, Jul 2026): HCA shows revenue (q1 2026) ~$19.1 billion, up ~4% year over year, full-year 2026 revenue guidance ~$76.5 billion to $80.0 billion (reaffirmed), adjusted ebitda guidance (2026) ~$15.55 billion to $16.45 billion, net income (q1 2026) ~$1.6 billion, or ~$7.15 per diluted share; THC shows revenue (ttm) ~$21.4 billion, fy2025 net operating revenue ~$21.3 billion (up ~3.7%), fy2025 adjusted diluted eps ~$16.78 (up ~41%), ebitda margin ~22-23%.

HCA and THC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HCA and THC exposure against your real portfolio. It is not an investment adviser.